Blog

A semaglutide mixing chart shows the volume of bacteriostatic water needed to reconstitute a powder vial to a target concentration. For compounded semaglutide, the typical question is whether to mix a 5 mg vial to 2.5 mg/mL (add 2 mL water) or 5 mg/mL (add 1 mL water). The math is straightforward — final concentration equals total mg divided by total mL added — but the practical steps require care to avoid contamination and dosing errors.

Standard Mixing Chart

Note: total number of doses depends on the dose size. The table above shows starting-dose count (0.25 mg). Higher maintenance doses (2.4 mg) yield fewer total doses per vial.

The Math Behind Mixing

Concentration is total mg divided by total mL. Reconstitution does not add or remove semaglutide — it only dissolves the powder into water. So:

• 5 mg powder + 2 mL water = 5 mg ÷ 2 mL = 2.5 mg/mL
• 5 mg powder + 1 mL water = 5 mg ÷ 1 mL = 5 mg/mL
• 10 mg powder + 2 mL water = 10 mg ÷ 2 mL = 5 mg/mL

The math is simple; the failure modes are the procedural steps.

Why Bacteriostatic Water Matters

Bacteriostatic water for injection contains 0.9 percent benzyl alcohol as a preservative. The preservative prevents bacteria from growing in the vial once it has been punctured. Multi-dose vials are punctured many times over 4-6 weeks; without preservative, even sterile water can support bacterial growth between punctures.

Plain sterile water is NOT a substitute. The FDA has documented contamination cases where home-mixers used plain sterile water and developed infections from contaminated vials. Bacteriostatic water is widely available through pharmacies and is the standard.

Reconstitution Technique (Done by Pharmacy)

This should ideally be done by your licensed compounding pharmacy. If you receive a powder vial and bacteriostatic water with instructions to reconstitute, follow these general steps carefully:

1. Wash hands thoroughly and prepare a clean work surface
2. Wipe the rubber stoppers of both vials (powder and water) with alcohol pads
3. Draw the specified amount of bacteriostatic water into a sterile syringe
4. Insert the needle into the powder vial at an angle and slowly inject the water down the inside wall of the vial — do not blast directly onto the powder
5. Gently swirl the vial (do not shake) until the powder fully dissolves; this can take 1-2 minutes
6. Inspect the solution for clarity — discard if cloudy, discolored, or contains particles
7. Label the vial with the new concentration, mixing date, and beyond-use date
8. Store in the refrigerator at 36-46°F / 2-8°C

Shaking the vial vigorously damages the semaglutide peptide. Always swirl gently.

Why Letting the Pharmacy Mix Is Safer

FDA safety reports cite several home-mixing errors:

• Using the wrong volume of water (concentration error)
• Using plain sterile water instead of bacteriostatic (contamination risk)
• Shaking instead of swirling (peptide damage)
• Failing to label the new concentration (later dosing errors)
• Using non-sterile syringes or needles (contamination)
• Storing at incorrect temperature (peptide degradation)

Licensed compounding pharmacies have sterile conditions, validated procedures, and trained staff. Home mixing carries materially higher risk of contamination and dosing errors.

Beyond-Use Dating

Once reconstituted, compounded semaglutide has a beyond-use date (BUD) — the date after which the product should be discarded. Typical BUDs:

• Refrigerated, with preservative: 4-6 weeks (varies by pharmacy)
• Room temperature: 1-2 weeks or less
• Without preservative (plain sterile water): days only

Your pharmacy will provide the BUD for your specific product. Never use past the BUD; discard and request a refill.

Signs of Spoiled Reconstituted Semaglutide

Discard the vial if you see:

• Cloudiness or change in color (should be clear and colorless)
• Visible particles or sediment
• Bubbles or foam that don’t dissipate after gentle swirling
• Damage to the rubber stopper
• Date past the BUD

The Bottom Line

Semaglutide mixing is concentration math — total mg divided by total mL added equals the final concentration. The standard 5 mg vial reconstitutes to 2.5 mg/mL with 2 mL of bacteriostatic water, or to 5 mg/mL with 1 mL. Always use bacteriostatic water (not plain sterile water) and follow your pharmacy’s specific instructions exactly. The FDA has documented home-mixing errors; reconstitution by a licensed compounding pharmacy is safer. Consult your prescriber and pharmacist before mixing or injecting any compounded medication. For more on GLP-1 treatment options, see our hub.

Semaglutide with glycine is a compounded formulation in which the amino acid glycine has been added to the preparation, typically as a stabilizer or buffer. It is not FDA-approved, has not been studied in clinical trials, and the claimed benefits come from compounding-pharmacy marketing rather than peer-reviewed research. The FDA has issued multiple warnings about compounded GLP-1 products with non-approved additives. This article explains what the combination is, what claims are made about it, and what the safety and regulatory picture looks like.

What Glycine Is

Glycine is the simplest amino acid, found naturally in the body and in dietary protein. It plays roles in collagen formation, neurotransmission, and detoxification. As a dietary supplement, glycine is generally regarded as safe at gram-level oral doses. It has also been used as an excipient (inactive ingredient) in some FDA-approved injectable medications for pH buffering or stabilization purposes.

Why Compounding Pharmacies Add Glycine to Semaglutide

Compounding pharmacies cite several reasons:

• pH buffering: glycine can stabilize the pH of an injection solution, theoretically improving peptide stability over the storage period
• Reduced injection site irritation: some compounders claim glycine reduces local irritation, though this has not been demonstrated specifically with semaglutide
• Cost-driven differentiation: “semaglutide with glycine” is a marketing differentiator among many compounding pharmacies offering similar products
• Replacing brand-name excipients: Wegovy and Ozempic use specific buffers and stabilizers; compounding pharmacies use their own excipient blends, sometimes including glycine

None of these claims are validated in published clinical trials for semaglutide specifically.

What the FDA Says

The FDA has issued repeated warnings about compounded GLP-1 medications. Key concerns:

• Compounded versions are not reviewed for safety, efficacy, or quality by FDA
• Many contain non-approved additives (glycine, vitamin B12 / cyanocobalamin, and others)
• Some use semaglutide salt forms (semaglutide sodium, semaglutide acetate) that are not the same as the active ingredient in FDA-approved products
• Reports of dosing errors, contamination, and unsterile preparation
• FDA action against telehealth platforms for misleading claims about compounded GLP-1 drugs

The legal pathway for routine compounding of semaglutide narrowed in 2025-2026 as the FDA-declared shortage of brand-name product ended. Compounding may still occur in specific situations (patient-specific allergies to brand-name ingredients, for example), but mass compounding for routine use is no longer permitted in the same way.

Comparison: Brand-Name vs Compounded with Glycine

Reported Side Effects

The side-effect profile of compounded semaglutide with glycine appears similar to brand-name semaglutide — gastrointestinal symptoms (nausea, constipation, diarrhea), occasional injection-site irritation, and the same theoretical risks (pancreatitis, gallbladder disease, thyroid C-cell tumor warning). However, because compounded products are not standardized, reported side effects vary by pharmacy and batch.

Injection-site reactions are sometimes reported more frequently with compounded products than with brand-name pens, possibly due to differences in excipient formulation, sterility procedures, or syringe technique.

Practical Considerations If You Use Compounded Semaglutide with Glycine

1. Verify pharmacy licensing. Confirm your compounding pharmacy holds an active state license and, where applicable, 503A or 503B FDA designation.
2. Read the label carefully. Check the concentration, ingredients (active and inactive), expiration date, and storage instructions.
3. Confirm dose with prescriber. Get your dose in BOTH mg and units (based on the specific vial concentration).
4. Use the right syringe. U-100 insulin syringes are standard, but small-volume doses may need 0.3 or 0.5 mL syringes.
5. Track adverse events. Report unusual symptoms to your prescriber and to FDA MedWatch.
6. Refill carefully. Concentrations and excipients can vary between refills — always re-verify before injecting.

When Brand-Name Makes More Sense

If you can access brand-name semaglutide (Ozempic or Wegovy) with insurance coverage or manufacturer savings programs, the brand-name product offers:

• FDA-reviewed safety, efficacy, and manufacturing
• Fixed-dose pen (no math required)
• Consistent formulation between refills
• Manufacturer support line for adverse events
• Quality oversight at every step of production

The cost differential is real but the safety and quality differential is also real. Discuss the trade-offs with your prescriber and consider whether the cost savings of compounded versions justify the regulatory and quality differences for your situation.

The Bottom Line

Semaglutide with glycine is a compounded formulation, not an FDA-approved product. Glycine is added as a stabilizer or buffer for theoretical (not clinically validated) benefits. The FDA has warned about compounded GLP-1 products with non-approved additives. If you use this formulation, verify your pharmacy’s licensing, check the label carefully, confirm doses with your prescriber, and report any adverse events. Brand-name semaglutide offers FDA-reviewed quality and fixed-dose convenience at substantially higher cost. Consult your prescriber to determine which option fits your situation. For more on GLP-1 treatment options, see our hub.

Semaglutide at the 5 mg per milliliter concentration is a high-strength compounded formulation. Each unit on a standard U-100 insulin syringe delivers 0.05 mg of semaglutide, so the standard weight-loss titration doses translate to small unit counts: 5 units for the 0.25 mg starting dose, up to 48 units for the 2.4 mg maintenance dose. The chart below covers every dose in the standard weight-loss and diabetes titration schedules.

Quick Reference: Standard Doses at 5 mg/mL

Intermediate Doses (Sub-Standard Titration)

Some prescribers use finer titration steps to minimize side effects. Here are common intermediate doses:

Half-unit measurements (2.5, 7.5, 12.5) require a 0.3 mL low-dose insulin syringe with half-unit markings. Standard 1 mL U-100 syringes typically have only whole-unit markings.

How to Read a U-100 Insulin Syringe

A U-100 insulin syringe has tick marks at every 2 units (sometimes every 1 unit on 0.3 mL pediatric syringes). To draw up 5 units of 5 mg/mL semaglutide:

1. Pull the plunger to the 5-unit mark while the needle is in air
2. Insert needle into the rubber stopper of the vial
3. Push the plunger down to inject air into the vial
4. Invert the vial and slowly pull the plunger back to the 5-unit mark while keeping the needle below the liquid surface
5. Tap to remove any air bubbles, then adjust to exactly 5 units
6. Withdraw needle, prepare injection site, inject subcutaneously

Why 5 mg/mL Requires Extra Care

The higher concentration amplifies the consequences of any measurement error:

• 1-unit measurement error at 5 mg/mL = 0.05 mg dose difference (versus 0.025 mg at 2.5 mg/mL)
• 5-unit error at 5 mg/mL = 0.25 mg = a full titration step
• Pulling 10 units instead of 5 = doubling your starting dose

This is why FDA safety reports about compounded semaglutide overdoses often involve higher-concentration vials. Beginners or anyone uncertain about measurement may prefer the lower 2.5 mg/mL concentration, where small errors have smaller consequences.

Vial Stability and Storage

Compounded semaglutide at 5 mg/mL typically:

• Requires refrigeration (36-46°F / 2-8°C)
• Has 4-6 weeks stability after reconstitution at refrigerator temperature
• Can sit at room temperature for short periods (typically up to a few hours) during injection prep
• Should not be frozen — freezing damages the peptide
• Should be discarded if cloudy, discolored, or past the expiration date your pharmacy provides

Storage requirements vary by formulation; always follow the instructions provided by your compounding pharmacy.

Switching From 2.5 mg/mL to 5 mg/mL

If your pharmacy changes your vial concentration, recalculate your dose. The number of units to inject changes:

• If you were taking 40 units at 2.5 mg/mL (= 1.0 mg), you now take 20 units at 5 mg/mL (= 1.0 mg)
• If you were taking 96 units at 2.5 mg/mL (= 2.4 mg), you now take 48 units at 5 mg/mL (= 2.4 mg)

The mg dose stays the same; the unit count is halved when concentration doubles.

FDA Safety Reminders

Compounded semaglutide is not FDA-reviewed for safety or efficacy. The FDA has documented dosing errors, contamination issues, and unsafe additives in some compounded products. If you use compounded semaglutide:

• Verify the compounding pharmacy is licensed in your state
• Always check the concentration printed on the label
• Use the syringe type your pharmacy specifies
• Report adverse events to FDA MedWatch
• Consult your prescriber before any dose changes

The Bottom Line

At 5 mg/mL concentration, the standard weight-loss titration runs from 5 units (0.25 mg) to 48 units (2.4 mg). Each unit delivers 0.05 mg, so dosing errors have larger consequences than at lower concentrations. Always verify the concentration on your specific vial, use the appropriate U-100 insulin syringe, and double-check the math before each injection. Consult your prescriber for any dose changes and your pharmacist for vial-specific guidance. For more on GLP-1 treatment options, see our hub.

40 units of semaglutide equals 1.0 mg at the most common compounded concentration of 2.5 mg per milliliter. The conversion depends entirely on the concentration of your specific vial, which varies by compounding pharmacy. This guide explains the math and how to avoid the dosing errors the FDA has flagged as a leading cause of compounded GLP-1 safety reports.

The Basic Math

Insulin syringe units are a measure of volume, not mass. On a standard U-100 insulin syringe (the type usually used for compounded semaglutide):

• 100 units = 1.0 mL
• 10 units = 0.1 mL
• 1 unit = 0.01 mL

To convert units to mg of semaglutide, you need to know the concentration of your vial (in mg/mL). The formula is:

mg = units × (concentration in mg/mL) ÷ 100

So at 2.5 mg/mL concentration:

• 40 units × 2.5 mg/mL ÷ 100 = 1.0 mg

Conversion Table at Common Concentrations

The same number of units delivers very different doses depending on concentration:

Why This Matters: FDA Safety Concerns

The FDA has issued multiple safety warnings about compounded GLP-1 medications. Dosing errors have caused reports of:

• Severe nausea, vomiting, and dehydration requiring emergency care
• Hypoglycemia in patients combining compounded GLP-1 with insulin or sulfonylureas
• Hospitalization for pancreatitis
• Confusion when patients accustomed to one concentration switch to a pharmacy using a different concentration

The most dangerous error is interpreting “units” as mg directly — for example, drawing up 25 units thinking it equals 0.25 mg when at 2.5 mg/mL concentration it actually equals 0.625 mg (2.5 times the intended dose).

How to Avoid Dosing Errors

1. Verify concentration on every refill. Read the vial label carefully — concentration is usually printed clearly. Don’t assume your new vial matches the old one.
2. Use a U-100 insulin syringe. Compounded semaglutide is typically dosed with a 1 mL or 0.5 mL insulin syringe. Confirm with your pharmacy.
3. Confirm the dose with your prescriber. Your prescriber should give you the dose in BOTH mg and units (based on your vial concentration). If you only received one number, ask for clarification.
4. Write the math down. Keep a written note of your concentration, mg dose, and unit equivalent. Check it before every injection.
5. Don’t change concentrations mid-titration. If your pharmacy switches concentrations, ask your prescriber to recalculate your dose in units before the next injection.

Equivalent Doses to Brand-Name Semaglutide

Common brand-name semaglutide doses translated to mg (for reference):

Brand-Name Pens Skip the Math

Ozempic and Wegovy pens deliver pre-measured fixed doses with no calculation required. You select the dose on the pen dial, inject, and the pen administers the correct volume automatically. This eliminates the unit-to-mg conversion problem entirely. The trade-off is cost — brand-name pens cost roughly 5-10 times more per month than compounded semaglutide.

The Bottom Line

40 units of semaglutide equals 1.0 mg at the standard 2.5 mg/mL compounded concentration, but the conversion is different at other concentrations. Always verify the concentration on your specific vial before calculating doses, use a U-100 insulin syringe, and confirm the dose with your prescriber. Dosing errors with compounded semaglutide are a documented FDA safety concern. Brand-name pens eliminate the math entirely by delivering pre-measured doses. Consult your prescriber and pharmacist before injecting any compounded medication. For more on GLP-1 treatment options, see our hub.

Semaglutide reaches peak blood levels 1-3 days after your first injection and starts reducing appetite within the first week. Meaningful weight loss usually appears within 4-12 weeks, and full A1C reduction takes 8-12 weeks at therapeutic doses. Because the drug requires a 16-week dose escalation period (for weight loss formulations), full effect is not reached until at least week 17. Individual response varies widely; some people see dramatic results in the first month, others see slower onset.

Phase 1: Days 1-7 (Appetite Reduction Starts)

After your first 0.25 mg starting dose, semaglutide reaches peak blood levels in 1-3 days. The drug crosses into brain regions that regulate hunger and starts signaling fullness through GLP-1 receptors. Most people report reduced appetite, smaller meal portions, and earlier satiety within the first 3-7 days.

Some people also notice food preference changes (sweet foods less appealing, alcohol less enjoyable) and reduced “food noise” — the constant background thoughts about food. These effects are subjective and not universal.

Side effects (nausea, mild GI upset) often appear in this same window, peaking 1-2 days after the injection.

Phase 2: Weeks 1-4 (Initial Weight Loss)

At the 0.25 mg starting dose, weight loss is modest — average 1-3 pounds in the first month. This early loss is primarily appetite-driven: you’re eating less without forcing it. Some loss may also be water weight as glycogen stores deplete with reduced carbohydrate intake.

A1C and fasting glucose start to drop in people with diabetes during this phase, though the changes are still building toward steady-state.

Phase 3: Weeks 4-16 (Dose Escalation)

The 16-week titration schedule for Wegovy increases the dose every 4 weeks (0.25, 0.5, 1, 1.7, then 2.4 mg). Each dose increase produces a renewed wave of appetite suppression and often a renewed wave of side effects.

By week 12, the average STEP-1 trial participant had lost about 6 percent of body weight on the path to higher doses. The average participant was not yet at the 2.4 mg maintenance dose at this point.

Phase 4: Weeks 17-68 (Maintenance Dose)

Once at the 2.4 mg maintenance dose, the drug reaches steady-state blood levels and maximum effect. Weight loss continues at a roughly linear rate for the next several months, then begins to plateau as the body adapts.

The STEP-1 trial showed average weight loss timelines at 2.4 mg:

For Diabetes (Ozempic) Timeline

The diabetes dose escalation is faster — 0.25 mg for 4 weeks, then 0.5 mg for 4 weeks, then optional 1 mg or 2 mg. Full A1C effect typically appears by week 12-16 at the maintenance dose. Average A1C reduction is about 1.5-2 percentage points at the 1 mg dose.

Fasting glucose drops within the first week as the drug starts working; A1C lags because the test reflects average blood sugar over the prior 2-3 months.

Pharmacokinetics: Why It Takes Time

Semaglutide has a half-life of about 7 days. With weekly dosing, blood levels accumulate to steady state over approximately 5 weeks (4-5 half-lives). Until steady state, each weekly dose adds incrementally to total exposure.

This means even at a higher dose, the drug takes about 5 weeks to reach its full blood concentration. The body then adapts to the steady-state level over additional weeks, producing maximum appetite suppression and metabolic effects.

Why Individual Responses Vary

Several factors influence how quickly you’ll see results:

• Starting weight and metabolic profile: people with more weight to lose often see faster initial loss
• Dietary patterns: high-calorie liquids and snacking despite no hunger blunt the appetite-reduction effect
• Exercise: regular physical activity amplifies weight loss
• Sleep and stress: poor sleep raises cortisol and hunger hormones, working against the drug
• Genetics: some people are stronger or weaker responders for reasons not fully understood
• Comorbidities: hypothyroidism, PCOS, and certain medications can slow weight loss independent of semaglutide

About 14 percent of STEP-1 trial participants did not reach 5 percent weight loss at any point in 68 weeks. These “non-responders” exist for reasons not yet well characterized.

When to Reassess

Most prescribers reassess at three milestones:

1. Week 4-8: tolerability — are side effects manageable enough to continue titration?
2. Week 16-20: early efficacy — at maintenance dose, is weight loss progressing?
3. Week 52: long-term efficacy — total weight loss meaningful enough to continue indefinitely?

If you’ve been at the 2.4 mg maintenance dose for 12-16 weeks without meaningful weight loss, your prescriber may discuss switching to tirzepatide or adding adjunct therapies. For diabetes, A1C should drop within 3 months at the 1 mg dose; if not, a dose increase to 2 mg or adding another agent is typically considered.

The Bottom Line

Semaglutide starts affecting appetite within days but takes weeks to produce meaningful weight loss and A1C reduction. The 16-week dose escalation schedule for weight loss means full effect doesn’t appear until at least week 17. Average weight loss is about 6 percent at week 12, 10 percent at week 20, and 15 percent at week 68 on the 2.4 mg maintenance dose. Individual responses vary widely; if you’ve been at maintenance for 12-16 weeks without response, talk to your prescriber. For more on treatment options, see our hub.

The most common side effects of Wegovy are gastrointestinal — nausea, diarrhea, constipation, and vomiting — and they typically appear or worsen each time your dose is increased during the 16-week titration period. About 44 percent of trial participants reported nausea at some point, but most found it manageable and most successfully reached the 2.4 mg maintenance dose. Discontinuation from side effects was about 7 percent in the STEP trials. Below is a more complete picture of what to expect.

Most Common Side Effects (Gastrointestinal)

These are direct consequences of how Wegovy works. The drug slows stomach emptying, increases satiety signaling, and acts on receptors in the gut and brain. The body usually adapts over time.

Practical Management of GI Symptoms

For nausea: eat smaller meals more frequently, avoid greasy or spicy food, eat slowly, stay upright for at least 30 minutes after eating, drink ginger or peppermint tea, and stay hydrated. Bland foods (toast, rice, bananas) often help during peak nausea days.

For constipation: increase fiber gradually (sudden fiber increases worsen GI symptoms on Wegovy), drink at least 8 cups of fluid daily, walk after meals, and use over-the-counter options like polyethylene glycol if needed (ask your pharmacist first).

For diarrhea: identify and limit trigger foods (often dairy, high-fat foods, or artificial sweeteners), maintain electrolytes with oral rehydration solutions, and avoid loperamide for prolonged use without consulting your prescriber.

For vomiting: if persistent, call your prescriber — they may slow your titration schedule or hold your dose. Dehydration from vomiting can cause acute kidney injury, so don’t tough it out alone.

Serious But Less Common Side Effects

Pancreatitis. Acute pancreatitis has been reported with all GLP-1 receptor agonists. Symptoms include severe persistent upper abdominal pain (often radiating to the back), nausea, and vomiting. Stop Wegovy and seek immediate medical attention if these symptoms develop. The absolute risk is low (roughly 0.1-0.3 percent annually) but the condition can be life-threatening.

Gallbladder disease. Rapid weight loss is itself a risk factor for gallstones. Wegovy roughly doubles the rate of cholecystitis (gallbladder inflammation) compared to placebo in trials. Symptoms include right upper-quadrant pain, nausea after fatty meals, and fever. Call your prescriber for evaluation.

Acute kidney injury. Almost always secondary to dehydration from vomiting or diarrhea. Maintain hydration and report persistent GI symptoms.

Hypoglycemia. Wegovy itself rarely causes low blood sugar in people without diabetes. Risk increases substantially when combined with insulin or sulfonylureas; dose adjustments to those medications are often needed.

Increased heart rate. Wegovy increases resting heart rate by about 1-4 beats per minute on average. Usually clinically insignificant, but discuss with your prescriber if you have a history of arrhythmia.

Boxed Warning: Thyroid C-Cell Tumors

Wegovy carries an FDA boxed warning based on rodent studies showing dose-dependent and treatment-duration-dependent thyroid C-cell tumors. Whether this translates to human risk is unknown — no signal has emerged in clinical trials, but the trials are not long enough to detect rare tumors. Wegovy is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2).

Mental Health Considerations

The FDA has investigated reports of suicidal ideation in patients on GLP-1 drugs but has not found a causal link to date. Wegovy’s prescribing information notes the need to monitor for depression or suicidal thoughts. If you have a history of depression or suicidal ideation, discuss with your prescriber before starting and during treatment.

Hair Loss

Hair loss is reported by about 3 percent of Wegovy weight-loss trial participants versus 1 percent on placebo. This is usually telogen effluvium — temporary shedding triggered by rapid weight loss rather than a direct drug effect. Ensuring adequate protein (0.8-1.2 g/kg body weight) and micronutrient intake (iron, zinc, biotin, vitamin D) reduces risk and supports regrowth. Hair typically returns to normal density within 6-12 months after weight stabilizes.

Wegovy “Face” and Skin Changes

“Ozempic face” and similar terms describe facial volume loss from rapid weight loss. This is not a drug-specific effect — any rapid weight loss causes loss of facial fat. The change is largely cosmetic and varies by individual. Some users seek dermatologic interventions (filler, etc.) to address it; many adapt over time as the face stabilizes at the new weight.

When to Call Your Prescriber

Contact your prescriber promptly for:

• Severe persistent abdominal pain (especially radiating to the back)
• Persistent vomiting preventing fluid intake
• Signs of severe dehydration (dizziness, dark urine, confusion)
• Signs of allergic reaction (rash, swelling, breathing difficulty)
• Vision changes (rare but serious in patients with diabetic retinopathy)
• Yellowing of skin or eyes

The Bottom Line

Most Wegovy side effects are gastrointestinal, dose-dependent, and improve as your body adapts. Slow titration, smaller meals, hydration, and patience handle most symptoms. Serious side effects (pancreatitis, gallbladder disease, kidney injury) are uncommon but require prompt medical evaluation. The boxed warning about thyroid tumors is based on rodent data; human risk is unknown. About 7 percent of trial participants discontinued Wegovy from side effects, meaning the large majority tolerated treatment successfully. Consult your prescriber about any persistent or severe symptoms. For more on weight-loss treatment options, see our hub.

Liraglutide and semaglutide are both GLP-1 receptor agonists used to treat type 2 diabetes and, in higher doses, chronic weight management. The two biggest practical differences are dosing frequency (liraglutide is daily, semaglutide is weekly) and effect size (semaglutide produces larger A1C reductions and more weight loss at standard doses). Both drugs share an essentially identical side-effect profile and the same boxed warnings.

What Each Drug Is

Both are GLP-1 receptor agonists — synthetic peptides that mimic glucagon-like peptide-1, a hormone your gut releases after eating. The hormone tells your pancreas to release insulin, slows stomach emptying, and signals fullness to the brain. Both ultimately do the same thing but at different speeds and with different durations of action.

Liraglutide is a once-daily subcutaneous injection. It is sold under two US brand names:

• Victoza — for type 2 diabetes, doses 0.6 mg, 1.2 mg, 1.8 mg daily
• Saxenda — for chronic weight management, doses 0.6, 1.2, 1.8, 2.4, 3.0 mg daily

Generic liraglutide became available in 2024 after Novo Nordisk’s exclusivity expired in several markets.

Semaglutide is a once-weekly subcutaneous injection (or daily oral tablet). It is sold under three US brand names:

• Ozempic — for type 2 diabetes, doses 0.25, 0.5, 1, 2 mg weekly
• Wegovy — for chronic weight management, doses 0.25, 0.5, 1, 1.7, 2.4 mg weekly
• Rybelsus — daily oral tablet for type 2 diabetes, doses 3, 7, 14 mg daily

Semaglutide is still brand-only as of 2026; no generic exists.

Head-to-Head Trial Data

The SUSTAIN-10 trial directly compared semaglutide 1 mg weekly versus liraglutide 1.2 mg daily in adults with type 2 diabetes over 30 weeks. Semaglutide outperformed liraglutide on both A1C reduction (-1.7% vs -1.0%) and body weight reduction (-5.8 kg vs -1.9 kg). Discontinuation rates from side effects were similar.

For weight loss specifically, indirect comparisons from separate trials (STEP for semaglutide, SCALE for liraglutide) suggest semaglutide produces about twice the average weight loss of liraglutide at maximum doses (~15% vs ~7-8% body weight reduction).

Dosing Schedules

Both drugs use slow titration to minimize gastrointestinal side effects.

Liraglutide for weight loss (Saxenda): starts at 0.6 mg daily for one week, increases by 0.6 mg weekly to a maximum of 3.0 mg daily. Total titration period: 5 weeks.

Semaglutide for weight loss (Wegovy): starts at 0.25 mg weekly for 4 weeks, increases monthly to a maximum of 2.4 mg weekly. Total titration period: 16 weeks.

Liraglutide’s daily dosing allows faster identification and adjustment of side effects (you know within hours whether you tolerated the dose). Semaglutide’s weekly dosing means side effects tend to cluster in the day or two after injection and ease as the week progresses.

Side Effects

Both share the same side-effect profile because both work through the same GLP-1 mechanism. The most common are gastrointestinal:

• Nausea (20-30% of users)
• Diarrhea (12-22%)
• Constipation (11-17%)
• Vomiting (6-15%)

Both carry the same FDA boxed warning about thyroid C-cell tumors based on rodent studies. Both should be avoided in patients with personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. Pancreatitis is a rare but serious risk for both.

Cost

Liraglutide is now generic in some markets, making it the cheaper option:

Generic liraglutide for weight loss (generic Saxenda) is expected to enter the US market over the coming years as more competitors arrive. Insurance coverage rules apply differently to each — confirm with your plan.

Which Should You Choose?

Semaglutide produces more weight loss and larger A1C reduction at standard doses, with the convenience of weekly dosing. Liraglutide is cheaper (especially as a generic), allows faster dose adjustment, and has a longer post-market safety record. If cost is the primary concern, generic liraglutide is often the better choice. If maximum efficacy is the priority and cost is manageable, semaglutide usually wins. Discuss the trade-offs with your prescriber. For more on diabetes treatment options, consult our hub.

The Bottom Line

Semaglutide and liraglutide are both GLP-1 receptor agonists with similar side-effect profiles and similar warnings. Semaglutide is more potent on average and dosed weekly; liraglutide is cheaper (now generic in some markets) and dosed daily. The choice depends on your A1C goal, weight goal, insurance, cost, and tolerance for daily versus weekly injection. Both require slow titration to minimize gastrointestinal side effects. Consult your prescriber to determine which fits your situation.

Wegovy is only sold as a once-weekly injection — there is no Wegovy pill on the market as of 2026. The oral form of semaglutide (the same active ingredient in Wegovy) is sold as Rybelsus, but Rybelsus is FDA-approved only for type 2 diabetes, not weight management. This is a common source of confusion because both products use the same molecule, and you may see articles or telehealth ads that conflate the two.

What Wegovy Is

Wegovy is a brand name for semaglutide manufactured by Novo Nordisk and FDA-approved in 2021 for chronic weight management in adults with obesity (BMI ≥ 30) or overweight (BMI ≥ 27) with at least one weight-related comorbidity. In 2024, the FDA expanded the approval to include adolescents 12 and older with obesity, and added a cardiovascular risk reduction indication for adults with cardiovascular disease and obesity. Wegovy is sold exclusively as a once-weekly subcutaneous injection.

What Rybelsus Is

Rybelsus is a brand name for oral semaglutide also manufactured by Novo Nordisk and FDA-approved in 2019. It is the only FDA-approved oral GLP-1 receptor agonist. Rybelsus is approved only for the treatment of type 2 diabetes mellitus in adults, taken once daily as a tablet. It is not approved for weight loss, despite using the same active ingredient as Wegovy.

Why No Wegovy Pill

Two factors explain why there’s no oral Wegovy:

Higher doses needed for weight loss. Weight-loss doses of semaglutide are substantially higher than diabetes doses. Wegovy maintenance dose is 2.4 mg per week; Rybelsus tops out at 14 mg per day. Delivering enough oral semaglutide to match the weight-loss effect of injectable Wegovy requires significantly higher oral doses than those in Rybelsus.

Bioavailability challenges. Semaglutide is a peptide. Peptides are normally destroyed by stomach acid and digestive enzymes. Rybelsus solves this with a co-formulated absorption enhancer (sodium N-(8-(2-hydroxybenzoyl)amino)caprylate, or SNAC), which temporarily neutralizes stomach acid and allows some semaglutide to be absorbed intact. Even so, oral bioavailability is roughly 0.4-1% of the dose, requiring much larger oral doses than injection.

Novo Nordisk ran the OASIS phase 3 trial program testing higher-dose oral semaglutide (25 mg and 50 mg daily) for weight loss in adults without diabetes. Results published in 2023 showed meaningful weight reduction, but as of 2026 FDA approval for a higher-dose oral weight-loss formulation has not occurred. If approved, it would likely be marketed under a new brand name rather than as “oral Wegovy.”

Comparison Table

How Wegovy Injections Work

Wegovy is sold in a single-dose pen with a fixed dose preloaded. You do not need to draw up the medication. The injection is given subcutaneously (just under the skin) in the abdomen, thigh, or upper arm, once per week. The needle is short and most people report minimal pain.

Dosing follows a slow titration schedule to minimize gastrointestinal side effects:

• Weeks 1-4: 0.25 mg weekly
• Weeks 5-8: 0.5 mg weekly
• Weeks 9-12: 1 mg weekly
• Weeks 13-16: 1.7 mg weekly
• Week 17 onward: 2.4 mg weekly (maintenance)

Pens are stored in the refrigerator unopened; once in use, a pen can be at room temperature for up to 28 days. Always check the FDA-approved patient instructions for storage details.

How Rybelsus Pills Work

Rybelsus has strict dosing rules to ensure absorption:

• Take on an empty stomach
• Swallow whole with no more than 4 ounces (120 ml) of plain water
• Wait at least 30 minutes before eating, drinking anything else, or taking other oral medications

If you miss these rules, the SNAC absorption enhancer cannot do its job and the dose is mostly wasted. Compliance is the practical challenge with Rybelsus.

What If You Want an Oral Weight-Loss Drug?

As of 2026, no FDA-approved oral GLP-1 weight-loss drug exists. Options include:

• Wait for FDA approval of high-dose oral semaglutide (under review at Novo Nordisk)
• Other oral weight-loss drugs (Qsymia, Contrave, Plenity) — different mechanisms, varying efficacy
• Off-label Rybelsus use (lower efficacy than Wegovy doses, rarely insurance-covered for weight loss)
• Injectable Wegovy or Zepbound (FDA-approved for weight loss)

Discuss the trade-offs with your prescriber. For more on injectable weight-loss options, see our treatment hub.

The Bottom Line

Wegovy is injection-only — there is no Wegovy pill. The oral semaglutide pill (Rybelsus) is FDA-approved only for type 2 diabetes, not weight loss, even though it uses the same active ingredient. Trials of higher-dose oral semaglutide for weight loss are complete but not yet FDA-approved. If you want oral semaglutide for weight management, no FDA-approved option exists today; consult your prescriber about whether off-label Rybelsus, other oral weight-loss drugs, or injectable Wegovy or Zepbound fits your situation.

Brand-name semaglutide lists for $968-$1,349 per month before insurance, with Ozempic and Rybelsus at the lower end and Wegovy at the high end. What you actually pay depends on which product you’re prescribed, your insurance plan, whether you qualify for the manufacturer’s savings card, and whether you choose brand-name or compounded versions. Insurance coverage is the single biggest variable — coverage for type 2 diabetes is broad, but coverage for weight loss is inconsistent and excluded from Medicare entirely.

List Prices by Product

Semaglutide is sold in the United States as three distinct products with different list prices:

List prices change periodically as manufacturers update their pricing, and your pharmacy may charge slightly different amounts based on local discounts. The values above are typical 2026 list prices in the US market.

Insurance Coverage

For type 2 diabetes (Ozempic, Rybelsus), insurance coverage is widespread. Most commercial plans, Medicare Part D, and many state Medicaid programs cover semaglutide for diabetes, usually with prior authorization. Step therapy is common — your plan may require you to try metformin first, or another GLP-1, before approving semaglutide.

For weight loss (Wegovy), coverage is much more limited. Many commercial plans either exclude weight-loss drugs entirely or require documentation of failed diet and exercise attempts plus a BMI threshold (typically 30, or 27 with comorbidity). Medicare Part D does not cover Wegovy for weight loss because federal law excludes weight-loss medications from Part D. This applies even though Medicare covers Ozempic for diabetes and now covers Wegovy for cardiovascular risk reduction in select patients (a separate FDA approval added in 2024).

Manufacturer Savings Programs

Novo Nordisk offers savings cards and patient assistance programs:

• Ozempic savings card: Commercially insured patients can pay as little as $25 per 28-day supply for up to 24 months, subject to a monthly maximum benefit.
• Wegovy savings card: Similar structure for commercially insured patients with covered prescriptions.
• Patient assistance program: Free medication for uninsured patients who meet income limits (typically up to 400% of the federal poverty level).

Patients on Medicare, Medicaid, TRICARE, or other government insurance are not eligible for the savings cards under federal anti-kickback rules. The patient assistance program may help if you have no insurance at all.

Compounded Semaglutide

Compounded versions of semaglutide are sold by telehealth platforms and compounding pharmacies for roughly $150-$400 per month — substantially less than brand-name pricing. Compounding was permitted under FDA rules during the FDA-declared shortage of brand-name semaglutide (2022-2024). Once the shortage ended, the legal pathway for routine compounding narrowed significantly.

The FDA has issued multiple safety warnings about compounded GLP-1 drugs, including reports of dosing errors, contaminated products, and platforms that misrepresent compounded drugs as FDA-approved. Compounded versions are not FDA reviewed for safety or efficacy. Some compounded products contain non-pharmaceutical-grade semaglutide salts or are mixed with vitamins like B12 (sometimes labeled “semaglutide with cyanocobalamin”). Quality varies widely by source.

Pharmacy Discount Cards (GoodRx, etc.)

Third-party discount cards (GoodRx, SingleCare, RxSaver) negotiate prices with pharmacies. For brand-name semaglutide, the discount versus list price is typically modest — often 5-15% off — because the drugs are still under patent and not heavily discounted. Comparing across pharmacies and combining with the manufacturer savings card (where eligible) usually yields the lowest cost.

The 340B Program

If you receive care at a Federally Qualified Health Center, Ryan White HIV/AIDS clinic, or other 340B-eligible facility, semaglutide may be available at deeply discounted 340B pricing. This applies primarily to safety-net providers, not to commercial pharmacies.

How to Lower Your Cost

• Confirm your insurance covers your specific product (Ozempic vs Wegovy vs Rybelsus) before filling
• If commercially insured, apply for the manufacturer savings card before filling
• If uninsured, apply to the patient assistance program
• Ask your prescriber whether step therapy alternatives exist that your plan covers without prior auth
• Compare cash prices across multiple pharmacies using GoodRx or similar tools
• If considering compounded versions, verify the pharmacy’s licensing and read FDA safety warnings first

The Bottom Line

Semaglutide is expensive without insurance — roughly $1,000-$1,400 per month at list prices. Insurance coverage is broad for diabetes indications, much more limited for weight loss, and excluded from Medicare Part D for weight loss. Manufacturer savings cards can reduce commercial-insured out-of-pocket cost to $25 per month for eligible patients. Compounded versions exist at lower prices but carry FDA safety warnings. Confirm coverage, apply for available patient assistance, and discuss options with your prescriber before deciding which form and channel to pursue. For more on diabetes treatment approaches, consult your prescriber.

Tirzepatide produced about 5 percentage points more weight loss than semaglutide in the head-to-head SURMOUNT-5 trial, and slightly larger A1C reductions in earlier diabetes trials. Both drugs work by mimicking gut hormones that regulate blood sugar and appetite, but their mechanisms differ in one important way: semaglutide acts on a single receptor (GLP-1), while tirzepatide acts on two (GLP-1 and GIP). That difference, combined with newer trial data, has made the comparison one of the most-asked questions in diabetes treatment.

How Each Drug Works

Semaglutide is a GLP-1 receptor agonist. It mimics glucagon-like peptide-1, a hormone your gut releases after eating. The hormone tells your pancreas to release insulin, slows stomach emptying, and signals fullness to the brain. The result is lower post-meal glucose, smaller appetite, and reduced food intake.

Tirzepatide does all of the above but adds a second receptor target: GIP (glucose-dependent insulinotropic polypeptide). GIP works alongside GLP-1 in the natural gut hormone response. By engaging both pathways, tirzepatide is theorized to amplify the same effects more strongly than GLP-1 alone, though the exact contribution of GIP activation to weight loss is still debated among researchers.

Head-to-Head Trial Results

The most direct comparison is SURMOUNT-5, a 72-week trial published in the New England Journal of Medicine in 2025 that randomized 751 adults with obesity (but without diabetes) to maximum-tolerated doses of either drug. Tirzepatide outperformed semaglutide on every primary and secondary outcome measured.

For type 2 diabetes outcomes specifically, the SURPASS trial program for tirzepatide and the SUSTAIN program for semaglutide showed tirzepatide achieved A1C reductions roughly 0.3-0.5 percentage points larger than semaglutide at comparable doses, though the trials were not designed as direct comparisons.

Brand Names and Approved Indications

Semaglutide is sold under three brand names in the United States:

• Ozempic — weekly injection, FDA approved for type 2 diabetes
• Wegovy — weekly injection, FDA approved for chronic weight management
• Rybelsus — daily oral tablet, FDA approved for type 2 diabetes

Tirzepatide is sold under two brand names:

• Mounjaro — weekly injection, FDA approved for type 2 diabetes
• Zepbound — weekly injection, FDA approved for chronic weight management and obstructive sleep apnea with obesity

Insurance coverage depends on indication. Diabetes formulations are more often covered; weight-loss formulations face more frequent prior authorization or denial. Off-label prescribing of Ozempic for weight loss continues despite the existence of Wegovy, often driven by formulary access.

Side Effect Comparison

Both drugs share an essentially identical side-effect profile because both work primarily through GLP-1 signaling. The most common side effects are gastrointestinal and dose-dependent:

• Nausea: 20-30% of users at typical doses; peaks during dose escalation
• Diarrhea: 12-22%
• Constipation: 11-17%
• Vomiting: 6-15%
• Decreased appetite: expected effect, not necessarily adverse

Both carry FDA boxed warnings about thyroid C-cell tumors based on rodent studies. Both should be avoided in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. Pancreatitis is a rare but serious risk for both. Tirzepatide showed slightly higher rates of nausea and diarrhea in some studies, but the difference is not clinically dramatic and individual variation is large.

Dosing Schedules

Both drugs use a slow titration schedule to minimize gastrointestinal side effects. Semaglutide for diabetes starts at 0.25 mg weekly for 4 weeks, then 0.5 mg, then optionally 1 mg, with a maximum of 2 mg. Semaglutide for weight loss (Wegovy) titrates monthly to 2.4 mg.

Tirzepatide starts at 2.5 mg weekly and increases by 2.5 mg every 4 weeks up to a maximum of 15 mg. The more granular titration steps may make tolerability management easier for some patients.

Cost Considerations

Both drugs are expensive without insurance — list prices range from about $1,000 to $1,400 per month. Manufacturer savings cards and patient assistance programs can reduce costs for eligible patients. The compounded versions of both drugs are sold at substantially lower prices through telehealth platforms, but the FDA has issued repeated warnings about safety, dosing accuracy, and contamination risks with compounded GLP-1 medications.

Which Should You Choose?

The honest answer is that this is a clinical decision driven by your individual goals, insurance, and tolerability — not a contest with a single winner. Tirzepatide produces more average weight loss and stronger A1C reductions in head-to-head data, but semaglutide has a longer post-market safety record and more diverse formulation options (including the oral Rybelsus). For many patients, the practical question becomes which one your insurance covers and which dose escalation you tolerate better. Both are considered first-line options by current American Diabetes Association guidelines for people who need both glycemic control and meaningful weight loss.

The Bottom Line

Tirzepatide is more potent on average for both weight loss and A1C reduction, with head-to-head trial data showing a meaningful gap in efficacy. Semaglutide remains a strong option with a longer track record and more formulation flexibility. The drugs share the same gastrointestinal side-effect profile and similar safety warnings. Your prescriber should match the choice to your A1C goal, weight-loss goal, insurance coverage, and tolerance to dose escalation. Consult your doctor before starting, switching, or stopping either medication.